Well-connected, Gilead-backed biotech gets another stack of cash to pursue CAR-Ts for autoimmune disease

Almost exactly two years after its debut at the 2020 JP Morgan confab — and on the heels of a new partnership with the gene editing experts at Intellia — a Gilead-backed, autoimmune disease-focused startup has returned to the well with a clearer outline of just...

Click to view original post